Archive for the ‘NYSE Opening Bell’ Category
Emergent Biosolutions Celebrates Initial Public Offering; Ceo To Ring Opening Bell On The NYSE
Image via Wikipedia
GAITHERSBURG, MD., November 21, 2006—Emergent BioSolutions Inc. (NYSE: EBS), a biopharmaceutical company that develops vaccines and therapeutics for biodefense and commercial applications and manufactures the only anthrax vaccine approved by the (FDA), today announced it will be celebrating the Company’s recently completed initial public offering with the ringing of the opening bell [...]
Posted on July 5, 2009 at 2:32 am by admin · Permalink
· Leave a comment
In: Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, NYSE Opening Bell, U.S. Food and Drug Administration · Tagged with: Biotechnology and Pharmaceuticals, Business, Chief executive officer, Clinical trial, Company, Emergent BioSolutions, New York Stock Exchange, Private Securities Litigation Reform Act, U.S. Food and Drug Administration
In: Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, NYSE Opening Bell, U.S. Food and Drug Administration · Tagged with: Biotechnology and Pharmaceuticals, Business, Chief executive officer, Clinical trial, Company, Emergent BioSolutions, New York Stock Exchange, Private Securities Litigation Reform Act, U.S. Food and Drug Administration